ArticlePloS one2026
Automated retinal disease classification using deep learning and AlexNet with statistical models analysis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic Retinopathy, Cataract, and Glaucoma are major retinal diseases that require early detection to prevent irreversible vision loss. This study proposes a deep learning-based framework for the automated classification of retinal images into four categories: Normal, Diabetic Retinopathy, Cataract, and Glaucoma. The dataset was compiled from publicly available retinal imaging databases, including IDRiD and HRF. Four convolutional neural network architectures-EfficientNet-B0, EfficientNet-B7, a build-from-scratch model, and AlexNet-were evaluated using multiple performance metrics. Among these, AlexNet achieved the highest overall performance, attaining an accuracy of 93.65%, sensitivity of 94.39%, specificity of 98.05%, PPV of 93.65%, NPV of 97.95%, and an F1-score of 93.74%. EfficientNet-B7 followed with an accuracy of 92.82%, confirming the strength of transfer learning in retinal feature extraction. A five-fold cross-validation further validated AlexNet's robustness, yielding a mean R2 of 0.8891 with low variance, indicating consistent generalization across folds. Computational efficiency analysis showed that AlexNet achieved high diagnostic accuracy with a moderate processing time of approximately 14 minutes. Model interpretability using SHapley Additive exPlanations (SHAP) revealed that AlexNet highlighted clinically relevant retinal regions, such as the optic disc and macula, thereby enhancing transparency and clinical trust. In summary, the proposed framework demonstrates that interpretable deep learning models can deliver accurate, consistent, and explainable retinal disease classification, offering a foundation for real-time, AI-assisted ophthalmic screening systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.